MedTech Resources

Company

Sequenom

Funding, FDA decisions, device trials, adverse event reports and recalls filed under this company's name in public data. Records are matched by name, so a subsidiary or an unusual spelling can be missed.

Last checked: Nov 19, 2026Source: SEC EDGAR, openFDA and ClinicalTrials.govMethods & limitations

This company is not on our public-company list, so only this exact name is matched. Naming a company here is not a recommendation of it or of any security.

Financing

Not publicly listed. It has raised money in private placements reported to the SEC on Form D (filings through 2026Q3). A company with no recent filing may since have been acquired.

Private

Total raised (reported)

$183M

4 Form D offerings, 2009 to 2015

Equity

$53.1M

Stock sold for cash

Debt and convertible notes

$130M

Loans and notes sold to investors

Last known valuation

Unknown

Form D filings do not report valuation

Latest round: convertible note, $85.0M raised of $85.0M sought, first sale Jun 9, 2015, 10 investors.

Funding rounds (Form D)

One row per Form D offering, newest first. The amount raised is the latest amended figure. An offering can run for months and close in several tranches. Matched by company name, so check the filing.

First saleTypeRaisedRound sizeInvestorsExemption and agentFiling
Jun 9, 2015Convertible note

Issued in a merger or acquisition; not counted as money raised

$85.0M$85.0M10Rule 506(b)Agent: Lazard Feres & Co.Commissions $1.5MForm D ↗Jun 19, 2015
Sep 17, 2012Debt$130M$130M2Rule 506Form D ↗Sep 24, 2012
May 17, 2010Equity$51.6M$51.6M18Rule 506Agent: Lazard Capital Markets LLC, Jefferies & Company, Inc.Commissions $3.2MForm D ↗May 24, 2010
Dec 21, 2009Equity$1.5M$1.5M27Rule 506Form D ↗Dec 29, 2009

Company details

From the company's latest Form D.

Legal name
SEQUENOM INC
Headquarters
San Diego, United States
Incorporated
Delaware over five years before filing
Entity type
Corporation
Revenue range
Decline to Disclose
Industry filed under
Biotechnology

Executives, directors and promoters

As listed on the latest Form D.

  • Richard LernerDirector
  • Carolyn BeaverExecutive Officer
  • Daniel GrosuExecutive Officer
  • Myla Lai-GoldmanDirector
  • John FazioDirector
  • Charles SlacikDirector
  • Kenneth BuechlerDirector
  • William WelchExecutive Officer, Director
  • David PendarvisDirector
  • Dirk van den BoomExecutive Officer, Director
  • Ronald LindsayDirector
  • Robin WeinerExecutive Officer
  • Jeff LintonExecutive Officer

Not in public filings: valuations, share prices and investors' names. Private databases such as PitchBook and Crunchbase estimate these from press releases and surveys. Not every round is filed: companies raising under other exemptions, or from foreign investors only, may not file Form D. Nothing here is investment advice.

Investors

5%+ shareholders from SEC Schedule 13D/13G filings since Dec 1, 2024, and SBIR/STTR grants (NIH through Nov 10, 2026, other agencies through 2023). Venture investors in private rounds are not in public filings.

No 5%+ shareholder filings or SBIR grants found under the name Sequenom.

Latest FDA decisions

Search the Clearance Tracker

No 510(k), De Novo or PMA decisions under this name since 2015.

Device trials

Trials on ClinicalTrials.gov that list this company as lead sponsor, most recently updated first.

Open in the Trial Radar
  • NCT04595201 · 20,000 participants · Start Oct 13, 2020 · Primary completion Sep 1, 2026

    Device: NIPT · For: Pregnancy

    Sites: Westborough, Massachusetts

  • NCT04364503 · 2,000 participants (planned) · Start Mar 17, 2018 · Primary completion Mar 17, 2030

    Device: Multiple interventions depending on diagnostic test being run. · For: Pregnancy Related; Cancer; Infectious Disease

    Sites: Los Angeles, California; San Diego, California; South San Francisco, California · 9 sites in all

  • NCT06008457 · 1,600 participants · Start Apr 17, 2023 · Primary completion May 31, 2025

    Device: Labcorp COVID-19+Flu+RSV Test Home Collection Kit · For: COVID-19 Respiratory Infection; Influenza A; Influenza Type B and 1 more

    Sites: Pasadena, California

  • NCT04774640 · 9 participants · Start May 29, 2014 · Primary completion Apr 30, 2018

    Device: MaterniT GENOME · For: Copy Number Variations

    Sites: New York, New York

  • NCT01597063 · 3,333 participants · Start Jul 2012 · Primary completion Feb 2014

    Device: SEQureDx Trisomy Test · For: Aneuploidy; Down Syndrome; Noninvasive Prenatal Screening

    Sites: Mobile, Alabama; Chandler, Arizona; Phoenix, Arizona · 27 sites in all

  • NCT01650948 · 100 participants · Start Jul 2012 · Primary completion Dec 2013

    Device: RetnaGene AMD LDT · For: Age-related Macular Degeneration

    Sites: San Francisco, California; Lexington, Kentucky; Nashville, Tennessee

Reports received

0

Received Nov 1, 2025 to Nov 19, 2026

Malfunction reports

0

Injury reports

0

Death reports

0

Adverse event reports received per month

Reports that name this company as manufacturer, by the date FDA received them. The newest month is incomplete.

Search the MAUDE Monitor

No reports to chart for this view.

Device types named most often

Last 12 months, by FDA product code. A company that sells more gets more reports.

No device types to rank.

Brand names named most often

Last 12 months, as written on the reports. One product can appear under several spellings.

No brand names to rank.

Recent recalls

From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.

No recalls under this name in FDA's data.

Back to all tools

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.